基于干细胞的心脏疾病治疗的分子影像学。
Molecular imaging in stem cell-based therapies of cardiac diseases.
机构信息
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria.
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria.
出版信息
Adv Drug Deliv Rev. 2017 Oct 1;120:71-88. doi: 10.1016/j.addr.2017.07.012. Epub 2017 Jul 19.
In the past 15years, despite that regenerative medicine has shown great potential for cardiovascular diseases, the outcome and safety of stem cell transplantation has shown controversial results in the published literature. Medical imaging might be useful for monitoring and quantifying transplanted cells within the heart and to serially characterize the effects of stem cell therapy of the myocardium. From the multiple available noninvasive imaging techniques, magnetic resonance imaging and nuclear imaging by positron (PET) or single photon emission computer tomography (SPECT) are the most used clinical approaches to follow the fate of transplanted stem cells in vivo. In this article, we provide a review on the role of different noninvasive imaging modalities and discuss their advantages and disadvantages. We focus on the different in-vivo labeling and reporter gene imaging strategies for stem cell tracking as well as the concept and reliability to use imaging parameters as noninvasive surrogate endpoints for the evaluation of the post-therapeutic outcome.
在过去的 15 年中,尽管再生医学在心血管疾病方面显示出巨大的潜力,但干细胞移植的结果和安全性在已发表的文献中显示出了有争议的结果。医学影像学可能有助于监测和量化心脏内移植细胞,并连续描述心肌干细胞治疗的效果。在多种可用的非侵入性成像技术中,磁共振成像和正电子发射断层扫描(PET)或单光子发射计算机断层扫描(SPECT)核成像,是最常用于临床的方法,以跟踪体内移植干细胞的命运。在本文中,我们综述了不同的非侵入性成像方式的作用,并讨论了它们的优缺点。我们专注于干细胞追踪的不同体内标记和报告基因成像策略,以及使用成像参数作为非侵入性替代终点来评估治疗后结果的概念和可靠性。